Who Paid My Doc
Mario De Meireles
Geriatric Medicine Dearborn, MI Medical Doctor
NPI 1255335097 CMS profile 11896
23874 Kean St, Dearborn, MI 48124
General payments
$1,027
Research payments
$0
Ownership & investment interest
$0
Research they led as principal investigator
$165
Through program year 2022, Mario De Meireles of Dearborn, MI is reported in the CMS Open Payments database as having received $1,027 across 41 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $165 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 76th percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2022 | General | $37 | 2 | |
| 2021 | General | $79 | 5 | |
| 2020 | General | $14 | 1 | |
| 2019 | General | $896 | 33 |
Beside peers
- Mario De Meireles
- Geriatric Medicine median
- Middle half of Geriatric Medicine
- National median
In program year 2025, general payments to Mario De Meireles were reported at $0. Among 1,028 Geriatric Medicine profiles paid that year, the median was $123 and the middle half received between $35 and $408.
Show as a table
| Year | Mario De Meireles | Geriatric Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $896 | $122 | $40–$435 | $163 |
| 2020 | $14 | $98 | $25–$349 | $114 |
| 2021 | $79 | $125 | $34–$441 | $132 |
| 2022 | $37 | $124 | $36–$408 | $149 |
| 2023 | $0 | $121 | $41–$383 | $160 |
| 2024 | $0 | $134 | $41–$435 | $164 |
| 2025 | $0 | $123 | $35–$408 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 110 drugsPart D claims
12,157
Drug cost
$317,948
Branded share of claims
13.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ingrezza Valbenazine Tosylate | Brand | 11 | $79,385 | |
| Eliquis Apixaban | Brand | 386 | $71,381 | |
| Xarelto Rivaroxaban | Brand | 114 | $18,798 | |
| Nuedexta Dextromethorphan Hbr/Quinidine | Brand | 16 | $9,681 | |
| Jardiance Empagliflozin | Brand | 53 | $9,379 | |
| Entresto Sacubitril/Valsartan | Brand | 50 | $8,878 | |
| Atorvastatin Calcium | Generic | 934 | $7,996 | |
| Divalproex Sodium | Generic | 116 | $4,869 | |
| Fluphenazine Hcl | Generic | 45 | $4,605 | |
| Pantoprazole Sodium | Generic | 292 | $4,496 |
The 10 drugs with the highest cost, of 110 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 5 billing codesPaid by Medicare
$51,605
Medicare patients
84
Services billed
595
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Alzheimer's or dementia | 58% | |
| Arthritis | 50% | |
| Heart failure | 49% | |
| Ischemic heart disease | 45% | |
| Depression | 45% | |
| Diabetes | 42% | |
| COPD | 37% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
41 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Geriatric Medicine in Michigan
Related records
Geriatric Medicine in Michigan
Practitioners in the same specialty and state, ranked by reported value.
All Geriatric Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Michigan
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.